Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in-human (FIH), Open-Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors

Next Previous
Search
Trial Profile

A First-in-human (FIH), Open-Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 21 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Toripalimab (Primary) ; YH 001 (Primary)
  • Indications Adenocarcinoma; Carcinoma; Gastric cancer; Oesophageal cancer; Sarcoma; Solid tumours; Urogenital cancer; Uterine cancer
  • Focus Adverse reactions; First in man
  • Sponsors Eucure Biopharma

    • Most Recent Events

    • 19 Dec 2022 Status changed from recruiting to completed.
    • 07 Jun 2022 Results (n=24; data cut off date= 31 dec 2021) presented at the 58th Annual Meeting of the American Society of Clinical Oncology
    • 24 May 2022 According to an Eucure Biopharma media release, data from this study will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top